Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase. Belinostat was approved in 2014 for relapsed or refractory peripheral T-cell lymphoma.
Related Prodcuts:
Doxorubicin HCl; Epirubicin; Epirubicin HCl; Idarubicin HCl; Pirarubicin; Amrubicin; Amrubicin HCL; AMG 900; YK-4-279; AT-7519 HCL; Resminostat; Resminostat hydrochloride; Mizoribine; Daunorubicin hydrochloride